After his final contributions to the ASPET Journals Task Force wrapped up in 2024, long-time ASPET member Michael Jarvis, PhD, FASPET, HonFBPhS,
found himself in an unusual position. Having completed his term as Pharmacology Research & Perspectives Editor-in-Chief and member of ASPET’s Publications Committee in 2023, and having completed his three-year term on ASPET’s Council as President-Elect, President, and Past-President (2021–2023), also previously having served two consecutive terms as Journal of Pharmacology and Experimental Therapeutics (JPET) Editor-in-Chief (2010–2015), Mike finally had a rare chance to breathe.
As we approach the summer months, I’m pleased to turn our attention to a cornerstone of our community: connection. In the rapidly evolving landscape of pharmacology, staying connected—with peers, mentors, and collaborators—is essential. As you likely know, the ASPET Annual Meeting is perhaps the most impactful event we host each year to create connection, as we brought over 1,000 pharmacologists together in Portland, Oregon in April earlier this year.
ASPET’s newly elected Council members started their new positions July 1, 2025.
Rick G. Schnellmann, PhD, Honored by Southern Arizona VA, ASPET Welcomes New Members
Separating the Policy from the Noise: Evolving Guidelines on Animal Models and Open Access. The National Institutes of Health (NIH) continues to align its policies with the current Administration’s view on scientific priorities. Two recent NIH policies have been released that have caused an upheaval in an already tumultuous time for science.
A showcase of early-career scientists—what drives them and why pharmacology is important to them.
Recognizing Our Supporters, January–June 2025. ASPET gratefully acknowledges the following individuals and organizations for their support of our programs and initiatives.




